- Open
- 27.50
- High
- 27.50
- Low
- 27.50
- Close
- 27.50
- Change
- -0.50 (-1.82%)
- Volume
- 186
| 8 Oct 2026 | 07:00:04 | Capital Access Window |
| 2 Sept 2026 | 17:29:03 | Exercise of Warrants |
| 7 Aug 2026 | 13:28:03 | Exercise of Warrants |
| 20 Jul 2026 | 07:00:07 | Completion of Dosing in Toxicology Programme |
| 23 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 31 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 31 Dec 2023 | Annual Report and Accounts (to 2023-06-30) |
Sareum Holdings PLC is a biotechnology company focused on drug discovery and development, primarily targeting cancer and autoimmune diseases. Its key programs include SDC-1801, a selective TYK2/JAK1 inhibitor for autoimmune conditions like psoriasis, and SDC-1802, aimed at cancer applications, particularly in hematological cancers. The company utilizes outsourced resources for its research and development activities and seeks to advance its drug candidates through clinical trials while exploring partnerships for commercialization. Sareum operates primarily in the pharmaceutical sector and is based in the United Kingdom.
| 8 Oct 2026 | 07:00:04 | Capital Access Window |
| 2 Sept 2026 | 17:29:03 | Exercise of Warrants |
| 7 Aug 2026 | 13:28:03 | Exercise of Warrants |
| 20 Jul 2026 | 07:00:07 | Completion of Dosing in Toxicology Programme |
| 23 Dec 2025 | Annual Report and Accounts (to 2025-06-30) | |
| 31 Dec 2024 | Annual Report and Accounts (to 2024-06-30) | |
| 31 Dec 2023 | Annual Report and Accounts (to 2023-06-30) |
Sareum Holdings PLC is a biotechnology company focused on drug discovery and development, primarily targeting cancer and autoimmune diseases. Its key programs include SDC-1801, a selective TYK2/JAK1 inhibitor for autoimmune conditions like psoriasis, and SDC-1802, aimed at cancer applications, particularly in hematological cancers. The company utilizes outsourced resources for its research and development activities and seeks to advance its drug candidates through clinical trials while exploring partnerships for commercialization. Sareum operates primarily in the pharmaceutical sector and is based in the United Kingdom.
| 22 Jun 2026 |
| 09:40:15 |
| Publication of Phase 1 data on SDC-1801 in BJCP |
| 10 Oct 2025 |
| AIM movers: Genedrive stake increase and WH Ireland continues to fall |
| 13 Aug 2025 | Sareum Holdings — New collaboration cements focus on CNS |
| 3 Jun 2025 | Sareum Holdings — A decisive step towards Phase II |
| 10 Apr 2025 | Sareum Holdings — Broader pipeline, bigger milestones |
| 14 Mar 2025 | Sareum Holdings — New fund-raise and licence signal active 2025 |
| 22 Jun 2026 |
| 09:40:15 |
| Publication of Phase 1 data on SDC-1801 in BJCP |
| 10 Oct 2025 |
| AIM movers: Genedrive stake increase and WH Ireland continues to fall |
| 13 Aug 2025 | Sareum Holdings — New collaboration cements focus on CNS |
| 3 Jun 2025 | Sareum Holdings — A decisive step towards Phase II |
| 10 Apr 2025 | Sareum Holdings — Broader pipeline, bigger milestones |
| 14 Mar 2025 | Sareum Holdings — New fund-raise and licence signal active 2025 |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £113m | -0.0% | |
| £40m | -0.2% | |
SARSareum Holdings PLC | £38m | +0.3% |
| £24m | -0.6% | |
| £11m | +0.0% | |
| £11m | +1.8% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £113m | -0.0% | |
| £40m | -0.2% | |
SARSareum Holdings PLC | £38m | +0.3% |
| £24m | -0.6% | |
| £11m | +0.0% | |
| £11m | +1.8% |
